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Background:  Recent FDA boxed warning has highlighted the potential importance of CYP2C19 genotype-guided antiplatelet therapy in PCI 
patients. A rapid and inexpensive genetic test in the PCI patient may facilitate personalised antiplatelet therapy. The Verigene 2C19/CBS nucleic acid 
assay detects eleven allelic variants of the CYP2C19 gene and is designed for point-of-care testing. However, the feasibility and validation of the test 
has not yet been reported in patients undergoing cardiac catheterization.
Methods:  In this study the Verigene 2C19/CBS nucleic acid assay was used to determine the presence of CYP2C19 *2-*10, *13, and *17 alleles 
prior to angiography (n=100). The results were validated with bi-directional DNA sequencing.
Results:  Genotype was determined within 3 hours of blood drawing. The Verigene CYP2C19 assay identified *2 (n=2) and * 17 (n=2) homozygotes; 
*2 (n=26), *8 (n=1), *9 (n=1), *10 (n=1), and *17 (n=29) heterozygotes. Bi-directional sequencing confirmed 100% accuracy.
Conclusion: This is the first report to demonstrate that the Verigene 2C19/CBS nucleic acid assay is a promising point-of-care method to rapidly 
and correctly identify the genotype of the PCI patient for facilitation of personalized antiplatelet therapy.
